Vaxinano is a leading biotechnology company based in Lille, specializing in the development of prophylactic and therapeutic vaccines for infectious diseases in both human and animal health. With a focus on innovation, Vaxinano offers a cutting-edge vaccine platform that produces adjuvant-free vaccines. This platform not only enables the development of new vaccines but also enhances existing ones by replacing adjuvants and reducing the use of antibiotics.

The technology behind Vaxinano's vaccines is based on bio-sourced nanoparticles made from starch and lipids, manufactured using green chemistry principles. These powerful nanoparticles serve as an effective antigen delivery system, capable of crossing mucus barriers. The vaccines formulated with these nanoparticles can be administered through nasal or injectable routes.

Vaxinano has achieved significant breakthroughs in the field, including the development of the world's first inactivated vaccine against toxoplasmosis and an immunotherapeutic treatment for leishmaniasis. Moreover, Vaxinano is spearheading the development of inactivated vaccines without adjuvants administered nasally, showcasing evidence of efficacy against influenza and covid-19. Located in the Eurasanté park and occupying over 800m2 of state-of-the-art laboratories near Lille University Hospital, Vaxinano is at the forefront of scientific research in vaccine development.

Contact Vaxinano today to discover how their pioneering vaccines can protect and improve human and animal health